First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options.
Until recently, a dichotomy existed in the front-line approach of metastatic clear-cell renal cell carcinoma (mRCC). Specifically, patients received either targeted therapy or immunotherapy. Targeted therapy entailed use of agents blocking signaling through the vascular endothelial growth factor (VE...
| Publicado en: | Targeted Oncology Vol. 14; no. 6; pp. 639 - 646 |
|---|---|
| Autores principales: | , , , , |
| Formato: | review Journal Article |
| Publicado: |
Springer Nature
Dec2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139826885&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 139826885 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17762596 47DQ jtl: Targeted Oncology issn: 17762596 maglogo: N pubinfo: dt: Dec2019 vid: 14 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 139826885 139826885 NLM31595385 139826885 10.1007/s11523-019-00676-y NLM31595385 139826885 ppf: 639 ppct: 7 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options. aug: au: Loo, Vivian Salgia, Meghan Bergerot, Paulo Philip, Errol J. Pal, Sumanta K. affil: Department of Protocol Content Administration, City of Hope Comprehensive Cancer Center, Duarte, CA, USA sug: subj: Antineoplastic Agents, Combined Therapeutic Use Immunotherapy Methods Kidney Neoplasms Drug Therapy Carcinoma, Renal Cell Drug Therapy Survival Kidney Neoplasms Pathology Carcinoma, Renal Cell Pathology Drug Therapy Treatment Outcomes Scales ab: Until recently, a dichotomy existed in the front-line approach of metastatic clear-cell renal cell carcinoma (mRCC). Specifically, patients received either targeted therapy or immunotherapy. Targeted therapy entailed use of agents blocking signaling through the vascular endothelial growth factor (VEGF) receptor, such as cabozantinib, sunitinib, or pazopanib. Immunotherapy entailed dual therapy with nivolumab and ipilimumab, both checkpoint inhibitors for intermediate/poor International Metastatic RCC Database Consortium (IMDC)-risk disease patients. Within the past year, two datasets have emerged that led to recent approvals of combined therapy with VEGF and checkpoint inhibitors. These regimens (axitinib with either avelumab or pembolizumab) are among several that have been or will be evaluated for patients with newly diagnosed mRCC. We aim to facilitate treatment decisions through this comprehensive and contextualized overview of recent datasets in this therapeutic space. pubtype: Academic Journal doctype: review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|